Federal Cannabis Rescheduling & Schedule III Counsel

The April 2026 federal rescheduling action created a new divide in cannabis law. Certain FDA-approved cannabis drug products and marijuana products tied to qualifying state medical marijuana licenses have been moved to Schedule III. Other marijuana activity, including adult-use cannabis, remains in Schedule I unless and until further federal action is completed.

For cannabis operators, investors, lenders, landlords, and license holders, the issue is no longer simply whether marijuana has been “rescheduled.” The issue is which activity qualifies, which activity remains federally exposed, and how the business should respond.

Joseph A. Bondy advises cannabis businesses and stakeholders on federal rescheduling, DEA registration, Section 280E relief, medical/adult-use separation, administrative proceedings, and related litigation risk.

A bifurcated federal system

The current federal structure treats state-licensed medical cannabis differently from other cannabis activity. That distinction affects registration strategy, tax treatment, compliance obligations, contract drafting, diligence, and enforcement risk.

Medical cannabis operators may now need to evaluate DEA registration, operational separation, recordkeeping, and the preservation of Schedule III treatment. 

Adult-use operators remain in a different posture. They should not assume that the medical rescheduling order protects adult-use activity, eliminates federal illegality, or removes Section 280E exposure from all revenue streams.

[Read more about DEA Registration]

[Read more about Schedule III & 280E]

DEA registration for state medical cannabis businesses

The newly created DEA registration pathway may allow qualifying state medical marijuana licensees to seek federal registration as manufacturers, distributors, or dispensers of Schedule III cannabis. The registration analysis requires more than completing a form. Operators must assess license scope, ownership, business activities, medical/adult-use separation, compliance systems, tax posture, and the risk of future agency or court action.

[Read the DEA Application Guide]

Section 280E relief and tax strategy

Rescheduling may remove Section 280E from qualifying Schedule III medical cannabis activity, but the tax consequences are not uniform across every cannabis business. Dual-use operators, multi-entity structures, management companies, investors, and adult-use businesses require careful analysis.

The Treasury Department’s apparent support for transition-year and potentially retroactive relief makes documentation, amended-return strategy, protective refund claims, and expense allocation immediately important.

[Read more about Schedule III & 280E]

Adult-use cannabis remains unresolved

The broader administrative rescheduling process remains pending. DEA has scheduled further proceedings concerning cannabis not covered by the medical rescheduling order. Until that process is complete, adult-use cannabis businesses should continue to treat federal Schedule I status as a central risk.

That risk affects tax planning, licensing, financing, real estate, insurance, M&A diligence, and enforcement exposure.

Litigation risk: SAM v. Blanche, and the limits of bifurcated rescheduling

The bifurcated federal approach is likely to be tested in court. Challenges may focus on whether DOJ and DEA can separate state-licensed medical cannabis from other marijuana activity while relying on treaty-based scheduling authority, and whether the process complies with the Controlled Substances Act, administrative-law requirements, and the D.C. Circuit’s reasoning in NORML v. DEA.

Pending litigation, including SAM v. Blanche, may affect the stability of the April 2026 order, DEA registration decisions, 280E planning, investor diligence, and business contracts.

Operators should plan for multiple outcomes: implementation, stay, remand, narrowing construction, or vacatur.

Counsel for cannabis businesses during federal transition

Joseph A. Bondy, PLLC provides counsel on:

• Schedule III eligibility;
• DEA registration strategy;
• state-license and federal-compliance documentation;
• administrative hearing strategy;
• litigation-risk assessment;
• cannabis business disputes 
• enforcement defense where commercial, regulatory, and criminal exposure overlap.

Speak with counsel

The federal cannabis transition creates opportunity, but it also creates risk. Medical operators, adult-use operators, investors, lenders, and counterparties should not rely on headlines or assumptions about “rescheduling.”

Contact Joseph A. Bondy, PLLC to evaluate your cannabis business, DEA registration strategy, 280E position, and federal rescheduling risk.